EBR/GBR + SOF +/- RBV in Cirrhotic GT3 Subjects

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003187-37

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

(1) Objective: To evaluate the efficacy of each treatment arm of GZR/EBR (MK-5172A) in combination with Sofosbuvir (SOF) +/- Ribavirin (RBV) as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA <LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy. (2) Objective:To evaluate the safety and tolerability of GZR/EBR (MK-5172A) in combination with SOF +/- RBV.


Critère d'inclusion

  • Hepatitis C infection

Liens